4/16
01:18 pm
srpt
Sarepta Therapeutics (SRPT) had its "sell" rating reaffirmed by HC Wainwright. They now have a $5.00 price target on the stock.
Low
Report
Sarepta Therapeutics (SRPT) had its "sell" rating reaffirmed by HC Wainwright. They now have a $5.00 price target on the stock.
4/16
10:57 am
srpt
Roche to start new Elevidys study following setback in Europe [Yahoo! Finance]
Low
Report
Roche to start new Elevidys study following setback in Europe [Yahoo! Finance]
4/8
09:19 am
srpt
Sarepta Therapeutics (SRPT) had its price target raised by Royal Bank Of Canada from $18.00 to $19.00. They now have a "sector perform" rating on the stock.
Medium
Report
Sarepta Therapeutics (SRPT) had its price target raised by Royal Bank Of Canada from $18.00 to $19.00. They now have a "sector perform" rating on the stock.
4/1
10:48 am
srpt
Sarepta Therapeutics (SRPT) had its price target raised by Wedbush from $29.00 to $35.00. They now have an "outperform" rating on the stock.
Low
Report
Sarepta Therapeutics (SRPT) had its price target raised by Wedbush from $29.00 to $35.00. They now have an "outperform" rating on the stock.
4/1
10:48 am
srpt
Sarepta Therapeutics (SRPT) had its price target raised by Deutsche Bank Aktiengesellschaft from $12.00 to $14.00. They now have a "sell" rating on the stock.
Low
Report
Sarepta Therapeutics (SRPT) had its price target raised by Deutsche Bank Aktiengesellschaft from $12.00 to $14.00. They now have a "sell" rating on the stock.
3/31
04:05 pm
srpt
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/26
11:28 am
srpt
Sarepta Therapeutics (SRPT) had its price target raised by Citigroup Inc. from $9.00 to $13.00. They now have a "sell" rating on the stock.
Low
Report
Sarepta Therapeutics (SRPT) had its price target raised by Citigroup Inc. from $9.00 to $13.00. They now have a "sell" rating on the stock.
3/26
10:41 am
srpt
Sarepta Therapeutics (SRPT) Soars 35.0%: Is Further Upside Left in the Stock? [Yahoo! Finance]
Neutral
Report
Sarepta Therapeutics (SRPT) Soars 35.0%: Is Further Upside Left in the Stock? [Yahoo! Finance]
3/26
08:19 am
srpt
Sarepta Therapeutics (SRPT) had its "underperform" rating reaffirmed by Needham & Company LLC.
Medium
Report
Sarepta Therapeutics (SRPT) had its "underperform" rating reaffirmed by Needham & Company LLC.
3/26
04:23 am
srpt
Assessing Sarepta Therapeutics (SRPT) Valuation After Early siRNA Trial Results Spark Share Price Rebound [Yahoo! Finance]
Neutral
Report
Assessing Sarepta Therapeutics (SRPT) Valuation After Early siRNA Trial Results Spark Share Price Rebound [Yahoo! Finance]
3/25
09:38 pm
srpt
Sarepta (SRPT) Skyrockets 35% on Morgan Stanley PT Hike, Stellar Trial Results [Yahoo! Finance]
Medium
Report
Sarepta (SRPT) Skyrockets 35% on Morgan Stanley PT Hike, Stellar Trial Results [Yahoo! Finance]
3/25
08:05 am
srpt
Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1
High
Report
Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1
3/24
04:29 pm
srpt
Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1 [Yahoo! Finance]
High
Report
Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1 [Yahoo! Finance]
3/24
04:05 pm
srpt
Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1
High
Report
Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1
3/24
09:26 am
srpt
Sarepta Therapeutics: A $2B Business Priced Like It's Broken [Seeking Alpha]
Low
Report
Sarepta Therapeutics: A $2B Business Priced Like It's Broken [Seeking Alpha]
3/23
08:31 am
srpt
How FDA Review of Sarepta's ESSENCE Data At Sarepta Therapeutics (SRPT) Has Changed Its Investment Story [Yahoo! Finance]
Medium
Report
How FDA Review of Sarepta's ESSENCE Data At Sarepta Therapeutics (SRPT) Has Changed Its Investment Story [Yahoo! Finance]
3/19
10:44 am
srpt
Sarepta Therapeutics (SRPT) had its "outperform" rating reaffirmed by Oppenheimer Holdings, Inc.. They now have a $37.00 price target on the stock.
Low
Report
Sarepta Therapeutics (SRPT) had its "outperform" rating reaffirmed by Oppenheimer Holdings, Inc.. They now have a $37.00 price target on the stock.
3/19
08:44 am
srpt
Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53® [Yahoo! Finance]
Low
Report
Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53® [Yahoo! Finance]
3/19
08:30 am
srpt
Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53®
Low
Report
Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53®
3/16
08:59 am
srpt
Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne [Yahoo! Finance]
Low
Report
Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne [Yahoo! Finance]
3/16
08:33 am
srpt
Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne
Low
Report
Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne
3/12
08:02 pm
srpt
Sarepta Therapeutics (SRPT) was given a new $31.00 price target by Mizuho.
Medium
Report
Sarepta Therapeutics (SRPT) was given a new $31.00 price target by Mizuho.
3/10
11:02 am
srpt
Sarepta Therapeutics (SRPT) had its price target raised by Citigroup Inc. from $8.00 to $9.00. They now have a "sell" rating on the stock.
Low
Report
Sarepta Therapeutics (SRPT) had its price target raised by Citigroup Inc. from $8.00 to $9.00. They now have a "sell" rating on the stock.
3/7
12:36 pm
srpt
Assessing Sarepta Therapeutics (SRPT) Valuation After A Difficult Year For Shareholders [Yahoo! Finance]
Low
Report
Assessing Sarepta Therapeutics (SRPT) Valuation After A Difficult Year For Shareholders [Yahoo! Finance]
3/6
09:26 am
srpt
PPMD Joins Cooperative International Neuromuscular Research Group, Global Sponsors to Advance Expanded Duchenne Natural History Study [Yahoo! Finance]
Medium
Report
PPMD Joins Cooperative International Neuromuscular Research Group, Global Sponsors to Advance Expanded Duchenne Natural History Study [Yahoo! Finance]